Cantor Fitzgerald Analysts Give Aerie Pharmaceuticals, Inc. (AERI) a $69.00 Price Target

Cantor Fitzgerald set a $69.00 price target on Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) in a research report released on Thursday. The firm currently has a buy rating on the stock.

Other analysts have also issued research reports about the stock. Canaccord Genuity restated a buy rating on shares of Aerie Pharmaceuticals in a research note on Friday, September 22nd. Mizuho restated a buy rating and set a $70.00 price target on shares of Aerie Pharmaceuticals in a research note on Monday, October 16th. Zacks Investment Research lowered shares of Aerie Pharmaceuticals from a hold rating to a sell rating in a research note on Tuesday, October 10th. Stifel Nicolaus restated a buy rating and set a $70.00 price target on shares of Aerie Pharmaceuticals in a research note on Friday, July 28th. Finally, BidaskClub upgraded shares of Aerie Pharmaceuticals from a strong sell rating to a sell rating in a research note on Monday, July 24th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have given a buy rating to the stock. Aerie Pharmaceuticals currently has a consensus rating of Buy and an average target price of $71.43.

Aerie Pharmaceuticals (NASDAQ:AERI) traded down $1.00 during trading hours on Thursday, hitting $58.70. 378,123 shares of the stock traded hands, compared to its average volume of 432,440. The company has a debt-to-equity ratio of 0.78, a current ratio of 15.24 and a quick ratio of 15.24. Aerie Pharmaceuticals has a 12 month low of $35.20 and a 12 month high of $66.25.

ILLEGAL ACTIVITY NOTICE: “Cantor Fitzgerald Analysts Give Aerie Pharmaceuticals, Inc. (AERI) a $69.00 Price Target” was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://sportsperspectives.com/2017/11/19/cantor-fitzgerald-analysts-give-aerie-pharmaceuticals-inc-aeri-a-69-00-price-target.html.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Ameritas Investment Partners Inc. grew its stake in shares of Aerie Pharmaceuticals by 11.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,665 shares of the company’s stock worth $140,000 after acquiring an additional 275 shares in the last quarter. Quantbot Technologies LP grew its stake in shares of Aerie Pharmaceuticals by 792.5% in the 3rd quarter. Quantbot Technologies LP now owns 2,981 shares of the company’s stock worth $144,000 after acquiring an additional 2,647 shares in the last quarter. BNP Paribas Arbitrage SA grew its stake in shares of Aerie Pharmaceuticals by 2,711.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,711 shares of the company’s stock worth $195,000 after acquiring an additional 3,579 shares in the last quarter. Amalgamated Bank bought a new stake in shares of Aerie Pharmaceuticals in the 2nd quarter worth $204,000. Finally, Palisade Capital Management LLC NJ bought a new stake in shares of Aerie Pharmaceuticals in the 2nd quarter worth $212,000. Hedge funds and other institutional investors own 95.71% of the company’s stock.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply